Protonix Granule, Delayed Release
NDC Package 0008-0844-02
Package Information
Protonix (pantoprazole sodium) granules is pantoprazole is used to treat certain stomach and esophagus problems (such as acid reflux). This formulation utilizes a granule, delayed release delivery system. Marketed by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc., this product is identified by NDC 0008-0844 and is authorized under FDA application NDA022020.
Identification & Billing
- RxCUI: 251872 - pantoprazole sodium 20 MG Delayed Release Oral Tablet
- RxCUI: 251872 - pantoprazole 20 MG Delayed Release Oral Tablet
- RxCUI: 251872 - pantoprazole 20 MG (as pantoprazole sodium sesquihydrate 22.56 MG) Delayed Release Oral Tablet
- RxCUI: 284400 - Protonix 40 MG Delayed Release Oral Tablet
- RxCUI: 284400 - pantoprazole 40 MG Delayed Release Oral Tablet [Protonix]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0008 - Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc.
- 0008-0844 - Protonix
- 0008-0844-02 - 30 PACKET in 1 CARTON / 1 GRANULE, DELAYED RELEASE in 1 PACKET (0008-0844-01)
- 0008-0844 - Protonix
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0008-0844-02 identifies a specific commercial package of 30 packet in 1 carton / 1 granule, delayed release in 1 packet (0008-0844-01) of Protonix Delayed-release, a human prescription drug labeled by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc.. This granule, delayed release is formulated for oral use and contains pantoprazole sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc. on February 29, 2008. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Pantoprazole is used to treat certain stomach and esophagus problems (such as acid reflux). It works by decreasing the amount of acid your stomach makes. This medication relieves symptoms such as heartburn, difficulty swallowing, and persistent cough. It helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Pantoprazole belongs to a class of drugs known as proton pump inhibitors (PPIs).
How is this Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00008084402. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.